Table 5.
Risk stratification of CLNM and LLNM for PTMC patients within Uni and Bil groups.
| Low Risk (TS ≤ 100) | Moderate Risk (100 < TS < 180) | High Risk (TS ≥ 180) | ||||
|---|---|---|---|---|---|---|
| (n = 197, %) | (n = 212, %) | (n = 173, %) | p Value | |||
| Uni group | ALL patients (n = 582) | Negative CLNM | 173 (87.8) | 144 (67.9) | 33 (19.1) | 0.000 |
| Positive CLNM | 24 (12.2) | 68 (32.1) | 140 (80.9) | |||
| Low risk (TS ≤ 100) | High risk (TS > 100) | |||||
| (n = 196, %) | (n = 36, %) | p value | ||||
| Patients with positive CLNM (n = 232) | Negative LLNM | 192 (98.0) | 10 (27.8) | 0.000 | ||
| Positive LLNM | 4 (2.0) | 26 (72.2) | ||||
| Low risk (TS < 80) | Moderate risk (80 ≤ TS < 100) | High risk (TS ≥ 100) | ||||
| (n = 14, %) | (n = 31, %) | (n = 90, %) | p value | |||
| Bil group | All patients (n = 135) | Negative LLNM | 14 (100.0) | 22 (71.0) | 24 (26.7) | 0.000 |
| Positive LLNM | 0 (0.0) | 9 (29.0) | 66 (73.3) | |||
| No risk factor | iNG only MDCLN > 0.5 cm only | Both two risk factors | ||||
| (n = 35, %) | (n = 10, %) (n = 19, %) | (n = 11, %) | p value | |||
| Patients with positive CLNM (n = 75) | Negative LLNM | 34 (97.1) | 8 (80.0) 11 (57.9) | 3 (27.3) | 0.000 | |
| Positive LLNM | 1 (2.9) | 2 (20.0) 8 (42.1) | 8 (72.7) | |||
PTMC, papillary thyroid microcarcinoma; CLNM, central lymph node metastasis; LLNM, lateral lymph node metastasis; iNG, ipsilateral nodular goiter; MDCLN, maximum diameter of positive central lymph node.